Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 13/1/2021
SIETES contiene 93213 citas

 
 
 1 a 20 de 154 siguiente >>
Presentar resultados
Seleccionar todas
1.Tiene citas relacionadas Cita con resumen
Torres A, Sibila O, Ferrer M, Polverino E, Menéndez R, Mensa J, Gabarrús A, Sellarés J, Restrepo MI, Anzueto A, Niederman MS, Agustí C. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 2015;313:677-86. [Ref.ID 98813]
2.Tiene citas relacionadas
Wunderink RG. Corticosteroids for severe community-acquired pneumonia: not for everyone. JAMA 2015;313:673-4. [Ref.ID 98812]
3.Tiene citas relacionadas
Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012;380:565-71. [Ref.ID 93575]
5.Tiene citas relacionadas
Anónimo. Why do the results of randomised and observational studies differ?. BMJ 2011;343:1128. [Ref.ID 91915]
6.Tiene citas relacionadas
Emberson J, Bennett D, Parish S, Armitage J, Collins R, on behalf of the Heart Protection Study Collaborative Group. C-reactive protein in the Heart Protection Study. Authors' reply. Lancet 2011;377:1918-9. [Ref.ID 91291]
7.Tiene citas relacionadas
Ridker PM, Koenig W, Kastelein JJP. C-reactive protein in the Heart Protection Study. Lancet 2011;377:1918. [Ref.ID 91290]
8.Tiene citas relacionadas
C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC). Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ 2011;342:425. [Ref.ID 90228]
9.Tiene citas relacionadas Cita con resumen
Keavney B. C reactive protein and the risk of cardiovascular disease. BMJ 2011;342:393-4. [Ref.ID 90224]
11.Tiene citas relacionadas
Després J-P. CRP: star trekking the galaxy of risk markers. Lancet 2011;377:441-2. [Ref.ID 90199]
12.Tiene citas relacionadas
Ridker PM, Genest J, Boekholdt SM, Libby P, Gotto AM, Nordestgaard BG, Mora S, MacFadyen JG, Glynn RJ, Kastelein JJP, for the JUPITER Trial Study Group. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet 2010;376:333-9. [Ref.ID 89009]
13.Tiene citas relacionadas
Hausenloy DJ, Opie L, Yellon DM. Dissociating HDL cholesterol from cardiovascular risk. Lancet 2010;376:305-6. [Ref.ID 89001]
14. Cita con resumen
Anónimo. Rosuvastatina (Crestor) y riesgo de diabetes. PAM 2010;34:440-1. [Ref.ID 88966]
15. Cita con resumen
Ridker PM, Glynn RJ. JUPITER, rosuvastatin, and the European Medicines Agency. Lancet 2010;375:2071. [Ref.ID 88667]
17.Tiene citas relacionadas
Habersberger J, Eisenhardt S, Peter K. C-reactive protein measurement and cardiovascular disease. Lancet 2010;375:1078. [Ref.ID 88176]
18.Tiene citas relacionadas
Boekholdt SM, Kastelein JJ. C-reactive protein measurement and cardiovascular disease. Authors' reply. Lancet 2010;375:1077-8. [Ref.ID 88175]
19.Tiene citas relacionadas
Wald DS, Bestwick JP. C-reactive protein measurement and cardiovascular disease. Lancet 2010;375:1077. [Ref.ID 88174]
Seleccionar todas
 
 1 a 20 de 154 siguiente >>